CINECA IRIS Institutional Research Information System

VALABREGA, Giorgio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.151
EU - Europa 3.740
AS - Asia 2.813
SA - Sud America 100
AF - Africa 87
OC - Oceania 73
Continente sconosciuto - Info sul continente non disponibili 10
Totale 12.974
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.987
CN - Cina 1.330
IT - Italia 1.128
SG - Singapore 490
GB - Regno Unito 381
IE - Irlanda 371
DE - Germania 368
FR - Francia 280
SE - Svezia 278
JP - Giappone 246
FI - Finlandia 148
IN - India 148
ES - Italia 145
PL - Polonia 127
CA - Canada 123
KR - Corea 120
VN - Vietnam 116
UA - Ucraina 109
ID - Indonesia 76
AU - Australia 64
NL - Olanda 62
DK - Danimarca 59
HK - Hong Kong 54
TR - Turchia 54
BE - Belgio 51
TW - Taiwan 45
BR - Brasile 43
MX - Messico 40
CH - Svizzera 36
RU - Federazione Russa 33
EG - Egitto 30
PT - Portogallo 28
TH - Thailandia 28
AT - Austria 27
IR - Iran 24
RO - Romania 24
NG - Nigeria 23
IL - Israele 21
PE - Perù 21
GR - Grecia 16
SA - Arabia Saudita 15
AR - Argentina 12
HU - Ungheria 12
CO - Colombia 11
CZ - Repubblica Ceca 11
HR - Croazia 11
CL - Cile 10
NZ - Nuova Zelanda 9
UZ - Uzbekistan 9
MY - Malesia 8
NO - Norvegia 8
AP - ???statistics.table.value.countryCode.AP??? 6
KW - Kuwait 6
MA - Marocco 6
SN - Senegal 6
TN - Tunisia 6
AM - Armenia 5
BY - Bielorussia 5
EU - Europa 4
LU - Lussemburgo 4
PK - Pakistan 4
SD - Sudan 4
SK - Slovacchia (Repubblica Slovacca) 4
ZA - Sudafrica 4
BG - Bulgaria 3
EC - Ecuador 3
RS - Serbia 3
AE - Emirati Arabi Uniti 2
BF - Burkina Faso 2
JO - Giordania 2
LB - Libano 2
LT - Lituania 2
MO - Macao, regione amministrativa speciale della Cina 2
PH - Filippine 2
UG - Uganda 2
BD - Bangladesh 1
CU - Cuba 1
EE - Estonia 1
ET - Etiopia 1
IQ - Iraq 1
IS - Islanda 1
KE - Kenya 1
KZ - Kazakistan 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
MK - Macedonia 1
QA - Qatar 1
SI - Slovenia 1
ZW - Zimbabwe 1
Totale 12.974
Salva come PNG Salva come JPEG
Città #
Chandler 626
Fairfield 448
Singapore 389
Dublin 358
Beijing 354
Houston 346
Santa Clara 342
Ashburn 330
Woodbridge 247
Ann Arbor 240
Seattle 213
Wilmington 186
Cambridge 170
Torino 155
Nyköping 137
Redwood City 127
Shanghai 109
Columbus 107
Jacksonville 102
Turin 95
Munich 93
Princeton 91
Guangzhou 90
Medford 90
Villeurbanne 86
Dearborn 85
Milan 81
New York 78
Rome 75
Jakarta 72
Warsaw 72
Pisa 67
Nanjing 65
Dong Ket 64
Tokyo 57
London 42
Boston 41
Fremont 41
Hangzhou 37
Helsinki 37
Boardman 35
San Diego 31
Wuhan 31
Chicago 28
Asyut 27
Duncan 27
Los Angeles 27
Taipei 27
Ottawa 26
Chengdu 25
Toronto 25
Madrid 23
Brussels 22
Hong Kong 21
Abuja 20
Kunming 20
Delhi 18
Sydney 18
Washington 18
Jinan 17
Paris 17
Barcelona 16
Hefei 16
Seoul 16
Silver Spring 16
Vienna 16
Changsha 15
Phoenix 15
São Paulo 15
Dallas 14
Hebei 14
Istanbul 14
Osaka 14
Shenyang 14
Upper Marlboro 14
Bangkok 13
New Delhi 13
Padova 13
Tianjin 13
Worcester 13
Zhengzhou 13
Amsterdam 12
Harbin 12
Lappeenranta 12
Norwalk 12
Riverton 12
St Louis 12
Valencia 12
Xian 12
Ankara 11
Naples 11
Philadelphia 11
Poznan 11
Verona 11
Berlin 10
Düsseldorf 10
Glasgow 10
Gothenburg 10
Newcastle 10
Varese 10
Totale 7.446
Salva come PNG Salva come JPEG
Nome #
PARP Inhibitors in Ovarian Cancer 2.685
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome 746
New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer 523
Metastatic breast cancer subtypes and central nervous system metastases. 290
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 283
Modeling ErbB2-p130Cas interaction to design new potential anticancer agents. 248
Checkpoint inhibitors in endometrial cancer: Preclinical rationale and clinical activity 238
Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis 206
Androgen receptor status predicts development of brain metastases in ovarian cancers 203
p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy 198
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer 191
Adoptive immunotherapy against ovarian cancer 177
Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy 173
Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions 170
Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer 164
Immune checkpoint inhibitors: A new opportunity in the treatment of ovarian cancer? 162
Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer. 153
Are cyclin-dependent kinases 4/6 inhibitors ready for prime time in estrogen-receptor positive metastatic breast cancer? 149
A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience 136
Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer 135
Secondary cytoreductive surgery, hyperthermic intraperitoneal intraoperative chemotherapy, and chemotherapy alone: A retrospective comparison of alternative approaches in relapsed platinum sensitive ovarian cancer 134
TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers 130
Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature 130
CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy 129
Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications 126
Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience 126
Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy 124
Abstract 3102: Identification of actionable cancer genes and treatment options for metastatic ovarian carcinomas using patient-derived xenografts and PDX-derived tumor cells 120
Reprogramming T-cells for adoptive immunotherapy of ovarian cancer 119
The 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA, 13-17 May, 2005 111
Immune checkpoint inhibitors in epithelial ovarian cancer: An overview on efficacy and future perspectives 111
Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. 110
Recent advances in the development of breast cancer vaccines. 108
Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series 108
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib 104
Assays of conventional chemotherapeutics and targeted drugs for ovarian cancer using patient derived models 103
Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity 102
PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma 100
Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer 95
ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells. 93
Identification of Actionable Cancer Genes and Treatment Options for Metastatic Ovarian Carcinomas using Patient Derived Xenografts (PDXs) and PDX Derived Tumor Cells (PDTCs) 93
Clinical implications of DNA repair defects in high-grade serous ovarian carcinomas 93
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer 92
Ovarian cancer immunotherapy: Turning up the heat 92
TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin. TOP2A as marker of response to PLD in ovarian cancer 86
Role of cyclin-dependent kinase inhibitors in endometrial cancer 84
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy 84
Women with synchronous or metachronous lung and ovarian cancer: A multi-institutional report 81
Role of Mediterranean diet in preventing platinum based gastrointestinal toxicity in gynecolocological malignancies: A single Institution experience 80
Author Correction: Modeling ErbB2-p130Cas interaction to design new potential anticancer agents (Scientific Reports, (2019), 9, 1, (3089), 10.1038/s41598-019-39510-w) 78
A Retrospective Analysis of the Activity and Safety of Oral Etoposide in Heavily Pretreated Metastatic Breast Cancer Patients. 75
Is there a role for immunotherapy in ovarian cancer? 74
Trastuzumab-related cardiotoxicity in the herceptin adjuvant trial 73
Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21) 69
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group 68
TGFalpha expression impairs Trastuzumab-induced HER2 downregulation 66
Veliparib: a new therapeutic option in ovarian cancer? 66
Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers 66
Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference San Antonio, TX, USA, 14-17 December 2007 65
The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality 65
Management of Metastatic Endometrial Cancer: Physicians' Choices Beyond the First Line. A MITO Survey 64
Concurrent radiotherapy does not affect adjuvant CMF delivery but is associated with increased toxicity in women with early breast cancer 63
Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. 63
Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study 62
Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition 60
Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers 60
Biomarkers of central nervous system involvement from epithelial ovarian cancer 59
Ovarian Cancer Cells in Ascites Form Aggregates That Display a Hybrid Epithelial-Mesenchymal Phenotype and Allows Survival and Proliferation of Metastasizing Cells 59
Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer. 57
Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer. 57
Immunotherapy in cervix cancer 56
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis 55
Immunotherapy for Cervical Cancer: Are We Ready for Prime Time? 55
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22) 54
Controversies in breast cancer: adjuvant and neoadjuvant therapy 54
Differences in parp inhibitors for the treatment of ovarian cancer: Mechanisms of action, pharmacology, safety, and efficacy 52
Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors 52
Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era 51
Translational research in ovarian cancer 50
Multitarget drugs: the present and the future of cancer therapy 48
Role of trastuzumab in the management of HER2-positive metastatic breast cancer. 48
Impact of covid-19 in gynecologic oncology: A nationwide italian survey of the sigo and mito groups 48
From Uterus to Brain: An Update on Epidemiology, Clinical Features, and Treatment of Brain Metastases From Gestational Trophoblastic Neoplasia 46
Trastuzumab-based combination therapy for breast cancer 45
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer 45
ASO Visual Abstract: Clinical and Histopathologic Predictors Signaling Recurrence of Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers 44
Searching for prognostic markers for Stage I epithelial ovarian cancer: A role for systemic inflammatory markers 43
Potential of afatinib in the treatment of patients with HER2-positive breast cancer. 42
Trastuzumab treatment in breast cancer 42
Trastuzumab Beyond Progression in Retrospective Analyses: An Issue of Equal Opportunities. 42
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study 41
Trastuzumab Beyond Disease Progression: Case Closed? 40
Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity? 39
Omission of Axillary Dissection after a Positive Sentinel Node Dissection may Influence Adjuvant Chemotherapy Indications in Operable Breast Cancer Patients. 33
In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study 30
Moderate Immunohistochemical Expression of HER-2 (2+) Without HER-2 Gene Amplification Is a Negative Prognostic Factor in Early Breast Cancer. 30
Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society 27
Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience 27
Correction: Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers 25
Lynch syndrome-associated endometrial cancer patient with a rare novel germline likely pathogenic variant of MSH2 gene: A case report 24
Totale 12.955
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.318
article - articoli 0
book - libri 0
conference - conferenze 1.038
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.356
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020865 0 0 0 0 0 219 129 112 136 93 67 109
2020/20212.148 67 172 270 172 175 173 157 153 178 204 140 287
2021/20222.082 149 132 103 161 135 144 157 170 161 148 329 293
2022/20232.425 211 222 94 198 229 481 184 152 257 86 172 139
2023/20241.959 211 221 104 147 145 257 158 166 40 158 136 216
2024/20251.509 72 180 149 231 671 206 0 0 0 0 0 0
Totale 13.276